TY - JOUR
T1 - Rna modifications and epigenetics in modulation of lung cancer and pulmonary diseases
AU - Teng, Pai Chi
AU - Liang, Yanwen
AU - Yarmishyn, Aliaksandr A.
AU - Hsiao, Yu Jer
AU - Lin, Ting Yi
AU - Lin, Tzu Wei
AU - Teng, Yuan Chi
AU - Yang, Yi Ping
AU - Wang, Mong Lien
AU - Chien, Chian Shiu
AU - Luo, Yung Hung
AU - Chen, Yuh Min
AU - Hsu, Po Kuei
AU - Chiou, Shih Hwa
AU - Chien, Yueh
N1 - Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/10/1
Y1 - 2021/10/1
N2 - Lung cancer is the leading cause of cancer‐related mortality worldwide, and its tumor-igenesis involves the accumulation of genetic and epigenetic events in the respiratory epithelium. Epigenetic modifications, such as DNA methylation, RNA modification, and histone modifications, have been widely reported to play an important role in lung cancer development and in other pulmonary diseases. Whereas the functionality of DNA and chromatin modifications referred to as epigenetics is widely characterized, various modifications of RNA nucleotides have recently come into prominence as functionally important. N6‐methyladosine (m6A) is the most prevalent internal modification in mRNAs, and its machinery of writers, erasers, and readers is well‐characterized. However, several other nucleotide modifications of mRNAs and various noncoding RNAs have also been shown to play an important role in the regulation of biological processes and pathology. Such epitranscriptomic modifications play an important role in regulating various aspects of RNA metabolism, including transcription, translation, splicing, and stability. The dysregulation of epi-transcriptomic machinery has been implicated in the pathological processes associated with carcin-ogenesis including uncontrolled cell proliferation, migration, invasion, and epithelial‐mesenchymal transition. In recent years, with the advancement of RNA sequencing technology, high‐resolution maps of different modifications in various tissues, organs, or disease models are being constantly reported at a dramatic speed. This facilitates further understanding of the relationship between disease development and epitranscriptomics, shedding light on new therapeutic possibilities. In this review, we summarize the basic information on RNA modifications, including m6A, m1A, m5C, m7G, pseudouridine, and A‐to‐I editing. We then demonstrate their relation to different kinds of lung diseases, especially lung cancer. By comparing the different roles RNA modifications play in the development processes of different diseases, this review may provide some new insights and offer a better understanding of RNA epigenetics and its involvement in pulmonary diseases.
AB - Lung cancer is the leading cause of cancer‐related mortality worldwide, and its tumor-igenesis involves the accumulation of genetic and epigenetic events in the respiratory epithelium. Epigenetic modifications, such as DNA methylation, RNA modification, and histone modifications, have been widely reported to play an important role in lung cancer development and in other pulmonary diseases. Whereas the functionality of DNA and chromatin modifications referred to as epigenetics is widely characterized, various modifications of RNA nucleotides have recently come into prominence as functionally important. N6‐methyladosine (m6A) is the most prevalent internal modification in mRNAs, and its machinery of writers, erasers, and readers is well‐characterized. However, several other nucleotide modifications of mRNAs and various noncoding RNAs have also been shown to play an important role in the regulation of biological processes and pathology. Such epitranscriptomic modifications play an important role in regulating various aspects of RNA metabolism, including transcription, translation, splicing, and stability. The dysregulation of epi-transcriptomic machinery has been implicated in the pathological processes associated with carcin-ogenesis including uncontrolled cell proliferation, migration, invasion, and epithelial‐mesenchymal transition. In recent years, with the advancement of RNA sequencing technology, high‐resolution maps of different modifications in various tissues, organs, or disease models are being constantly reported at a dramatic speed. This facilitates further understanding of the relationship between disease development and epitranscriptomics, shedding light on new therapeutic possibilities. In this review, we summarize the basic information on RNA modifications, including m6A, m1A, m5C, m7G, pseudouridine, and A‐to‐I editing. We then demonstrate their relation to different kinds of lung diseases, especially lung cancer. By comparing the different roles RNA modifications play in the development processes of different diseases, this review may provide some new insights and offer a better understanding of RNA epigenetics and its involvement in pulmonary diseases.
KW - Lung cancer
KW - Methylation
KW - N6‐methyladenosine
KW - Pulmonary diseases
KW - RNA epigenetics
UR - http://www.scopus.com/inward/record.url?scp=85116022383&partnerID=8YFLogxK
U2 - 10.3390/ijms221910592
DO - 10.3390/ijms221910592
M3 - Review article
C2 - 34638933
AN - SCOPUS:85116022383
SN - 1661-6596
VL - 22
JO - International Journal Of Molecular Sciences
JF - International Journal Of Molecular Sciences
IS - 19
M1 - 10592
ER -